New Drug Outperforms Erlotinib in NSCLC Trial | Lung Cancer Dispatch |

A new drug called dacomitinib proved more effective than erlotinib (Tarceva) in a recent clinical trial investigating non-small cell lung cancer (NSCLC) treatment. The results may be due to dacomitinib’s greater versatility—erlotinib targets only EGFR, while dacomitinib targets a whole family of proteins, including EGFR, that could contribute to tumor growth. Pfizer and SFJ Pharmaceuticals Group have announced plans to conduct a larger, multi-national clinical trial for dacomitinib.